ES2104156T3 - Peptido estimulante de linfocitos t citotoxicos especificos de virus de la hepatitis c. - Google Patents

Peptido estimulante de linfocitos t citotoxicos especificos de virus de la hepatitis c.

Info

Publication number
ES2104156T3
ES2104156T3 ES93915244T ES93915244T ES2104156T3 ES 2104156 T3 ES2104156 T3 ES 2104156T3 ES 93915244 T ES93915244 T ES 93915244T ES 93915244 T ES93915244 T ES 93915244T ES 2104156 T3 ES2104156 T3 ES 2104156T3
Authority
ES
Spain
Prior art keywords
peptide
ctl
cat
recognize
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93915244T
Other languages
English (en)
Inventor
Jay A Berzofsky
Mutsunori Shirai
Toshitaka Akatsuka
Stephen M Feinstone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2104156T3 publication Critical patent/ES2104156T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA CELULA T CITOTOXICA SENSIBLE A LA PROTEINA CODIFICADA POR LA REGION NS5 DEL VIRUS C DE LA HEPATITIS ERA DETERMINADO USANDO 28 PEPTIDOS DE NS5 QUE FUERON SELECCIONADOS POR UN ALGORITMO DE ANFIPATICIDAD COMO CANDIDATOS PARA LOS EPITOPES DE LA CELULA T. EN EL RATON BALB/C, UN EPITOPE SIMPLE RELATIVAMENTE CONSERVADO REPRESENTADO POR UN PEPTIDO SINTETICO DE RESIDUO-16 ERA REPRESENTADO POR LAS MOLECULAS (MHC) DEL COMPLEJO DE HISTOCOMPATIBILIDAD MAYOR DE CLASE I DD AL CONVENCIONAL CD4-CD8+CTL. UN PEPTIDO EJEMPLAR, QUE REPRESENTA LOS RESIDUOS DE ACIDO AMINO 2422-2437 DE LA POLIPROTEINA DEL CHIRON HCV1 AISLADO, TENIA LA SECUENCIA DE ACIDO AMINO MSYSWTGALVTPCAAE (SEQ ID NO:1). UNA LINEA CTL ESPECIFICA PARA ESTE PEPTIDO RECONOCIDA LAS DOS VARIANTES NATURALES CONOCIDAS DE ESTA SECUENCIA NS5, CADA UNA CON SUSTITUCIONES CONSERVADORAS. ASI, EL CTL PUEDE RECONOCER EL PRODUCTO DEL GEN HCV NS5, LA POLIMERASA RNA PROBABLE, EN ASOCIACION CON LAS MOLECULAS MHC DE CLASE I EN LAS CELULAS OBJETO DE MODELO Y DEBEN RECONOCER AL MISMO EPITOPE EN LOS HEPATOCITOS O CUALQUIER OTRAS CELULAS INFECTADAS CON EL VIRUS.
ES93915244T 1992-06-10 1993-06-10 Peptido estimulante de linfocitos t citotoxicos especificos de virus de la hepatitis c. Expired - Lifetime ES2104156T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/894,063 US5980899A (en) 1992-06-10 1992-06-10 Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells

Publications (1)

Publication Number Publication Date
ES2104156T3 true ES2104156T3 (es) 1997-10-01

Family

ID=25402543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915244T Expired - Lifetime ES2104156T3 (es) 1992-06-10 1993-06-10 Peptido estimulante de linfocitos t citotoxicos especificos de virus de la hepatitis c.

Country Status (11)

Country Link
US (1) US5980899A (es)
EP (1) EP0644894B1 (es)
JP (1) JP3510249B2 (es)
AT (1) ATE153031T1 (es)
AU (1) AU669193B2 (es)
CA (1) CA2135278C (es)
DE (1) DE69310734T2 (es)
DK (1) DK0644894T3 (es)
ES (1) ES2104156T3 (es)
GR (1) GR3024462T3 (es)
WO (1) WO1993025575A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU773000C (en) * 1994-07-27 2004-10-07 Csl Limited Polyepitope vaccines
NZ290089A (en) * 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
GB9618119D0 (en) 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
EP1037974B1 (en) 1997-12-11 2007-10-03 SmithKline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
AU6226100A (en) * 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2001056355A2 (en) 2000-02-04 2001-08-09 Duke University Human immunodeficiency virus vaccine
WO2001072331A1 (en) * 2000-03-31 2001-10-04 Vaccine Chip Technology Aps Immunostimulating properties of a fragment of tgf-beta
ATE502952T1 (de) * 2000-09-01 2011-04-15 Epimmune Inc Hla-bindungspeptide und ihre anwendungszwecke
AU2002259130A1 (en) * 2001-05-03 2002-11-18 Eli Lilly And Company Agents for treatment of hcv and methods of use
FR2828934B1 (fr) * 2001-08-27 2004-08-13 Inst Nat Sante Rech Med Test de l'immunite cellulaire par des peptides fixes sur support solide
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
CA2566506A1 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
US20070073039A1 (en) * 2005-09-29 2007-03-29 Chisari Francis V Peptides that inhibit viral infections
WO2007084568A2 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
US20210052721A1 (en) * 2018-03-16 2021-02-25 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
HU220204B (hu) * 1987-11-18 2001-11-28 Chiron Corp. HCV polipeptidek és HCV polinukleotidok, ilyen polinukleotidokat tartalmazó vektorok és ezekkel transzformált gazdasejtek, valamint HCV fertőzés kimutatására szolgáló diagnosztikumok és immunvizsgálati készlet
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines

Also Published As

Publication number Publication date
AU669193B2 (en) 1996-05-30
DE69310734D1 (de) 1997-06-19
CA2135278A1 (en) 1993-12-23
DE69310734T2 (de) 1998-01-15
US5980899A (en) 1999-11-09
GR3024462T3 (en) 1997-11-28
EP0644894B1 (en) 1997-05-14
DK0644894T3 (da) 1997-12-08
CA2135278C (en) 2005-08-09
ATE153031T1 (de) 1997-05-15
JP3510249B2 (ja) 2004-03-22
EP0644894A1 (en) 1995-03-29
WO1993025575A1 (en) 1993-12-23
JPH08501282A (ja) 1996-02-13
AU4530093A (en) 1994-01-04

Similar Documents

Publication Publication Date Title
ES2104156T3 (es) Peptido estimulante de linfocitos t citotoxicos especificos de virus de la hepatitis c.
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
ES2075901T3 (es) Sistemas de expresion de virus recombinantes de arn con cadena negativa y vacunas.
SE9004010D0 (sv) Viralt medel
ES2012739T3 (es) Diagnosticos y vacunas para nanbv.
DE69133228D1 (de) Dna-expressionssysteme basierend auf alphaviren
ATE236981T1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
DE69033425T2 (de) HCV-Isolat J-1
DK156592D0 (da) Human-h1-praeprorelaxin, -prorelaxin og -relaxin samt polypeptid med relaxinaktivitet og fremgangsmaade til sammenfoejning af a- og b-kaederne i human-h1-relaxin
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
ATA3552000A (de) Xylosyltransferase-gen
BR9815912A (pt) Cepa viral de hepatite b induzida por vacina e seus usos
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DK35891A (da) Praktisk taget rent, antigenisk peptid eller protein med en epitop af haemophilus influenzae, dets fremstilling og anvendelse
DK0651806T3 (da) Vacciner imod katteimmundeficiensvirus (FIV)
IT1249684B (it) Epitopi della proteina env del virus dell'epatite c.
DE69106141D1 (de) Non-a non-b sequenzen.
AR248047A1 (es) Procedimiento para la preparacion de una vacuna a base de virus del herpes bovina modificado tipo 1.
NO912387D0 (no) Rent faktor 1-protein, samt fremgangsmaate for fremstilling av proteinet.
BR9815913A (pt) Cepa viral de hepatite b humana mutante e seususos
PT89041A (pt) Metodo de preparacao de diagnosticos e vacinas nanbv
KR950000881A (ko) 새로운 한국형 씨(C)형 간염 바이러스 씨디엔에이(cDNA) 절편의 뉴클레오티드 서열 및 이로부터 유추된 아미노산 서열
TH62241A (th) ไบคูนินของคน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 644894

Country of ref document: ES